News & Press Releases

Mintz advised Wavecrest Growth Partners on its acquisition of Dealerware, a leading software platform for dealer fleet and mobility program management, connecting over 60,000 vehicles at nearly 2,000 dealerships and OEMs across the US and Canada.

Mintz advised Kpler, a global trade intelligence technology company backed by Five Arrows (Rothschild) and Insight Partners, on its acquisition of Bridgeton Research Group LLC, a provider of predictive analytics focused on Commodity Trading Advisors (CTAs) and systematic investment strategies across global commodities and financial markets.

Mintz is pleased to have represented Royal Philips, a global leader in health technology, in the sale of its Emergency Care business to Emergency Care Holdings, a platform backed by Bridgefield Capital. The Emergency Care business offers products that play a critical role in acute care management, both inside and outside the hospital, including cardiac resuscitation, such as automated external defibrillators, and emergency care devices for professional and consumer applications. Following the sale, the business now operates as Heartstream and continues to market select products under a brand license with Philips.

Mintz advised Altamira Technologies Corporation, an open-source technology company in the national security space, on its acquisition by Parsons Corporation, a leading national security and global infrastructure technology provider. The transaction is valued at $375 million, including $330 million in cash at closing and an additional $45 million earn-out contingent on 2026 EBITDA targets.

Mintz advised the placement agents in connection with a $1 billion registered direct offering of 19,000,000 shares of common stock and, in lieu of common stock, pre-funded warrants to purchase up to 41,790,274 shares of common stock. Each share of common stock and each pre-funded warrant was sold with a common stock warrant to purchase two shares of common stock. 

Mintz advised the underwriters in connection with a $661 million public offering by Praxis Precision Medicines of 2,543,800 shares of common stock (which includes 331,800 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $260.00 per share.